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Abstract
Background: Opportunistic invasive fungal infections are increasingly frequent in intensive care
patients. Their clinical spectrum goes beyond the patients with malignancies, and for example
invasive pulmonary aspergillosis has recently been described in critically ill patients without such
condition. Liver failure has been suspected to be a risk factor for aspergillosis.
Case presentation: We describe three cases of adult respiratory distress syndrome with sepsis,
shock and multiple organ failure in patients with severe liver failure among whom two had positive
Aspergillus antigenemia and one had a positive Aspergillus serology. In all cases bronchoalveolar
lavage fluid was positive for Aspergillus fumigatus. Outcome was fatal in all cases despite treatment
with voriconazole and agressive symptomatic treatment.
Conclusion: Invasive aspergillosis should be among rapidly raised hypothesis in cirrhotic patients
developing acute respiratory symptoms and alveolar opacities.
Background
Invasive pulmonary aspergillosis is a severe and often
lethal infection. It mainly occurs in patients with malig-
nancy who experience deep and prolonged neutropenia,
but there are other established risk factors (e.g. high-dose
long-term corticosteroid therapy or advanced forms of
AIDS) [1]. Invasive pulmonary aspergillosis has recently
been described in critically ill patients without malig-
nancy [2-4], and Aspergilluss is increasingly considered as
an emerging pathogen in non-hematological patients.
Among the non-hematological patients diagnosed with
invasive pulmonary aspergillosis in the critical care setting
were patients with Child C liver cirrhosis [3]. This condi-
tion has thus be considered as a possible risk factor for
invasive pulmonary aspergillosis, all the more so that
acute liver failure is known to promote fungal infection
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ness of clinicians managing patients with decompensated
cirrhosis, we report invasive pulmonary aspergillosis in
three such patients.
Case presentations
The three cases were diagnosed over a 18 months period,
in two different hospitals.
Case 1
A 54-year-old man was admitted for ascites and acute
renal failure revealing Child-Pugh stage C13 alcoholic cir-
rhosis. A liver biopsy showed severe acute alcoholic hepa-
titis and treatment with prednisolone 1 mg/kg a day was
started. Human immunodeficiency virus (HIV) serology
was negative, as were viral hepatitis B (HBV) and viral
hepatitis C (HCV) tests. Over the following 21 days, four
episodes of hemorrhagic shock from grade II esophageal
varices occurred. A transjugular intrahepatic portosys-
temic shunt was placed on day 21. On day 22, severe sep-
sis developed with middle lobe alveolar consolidation on
the chest x-ray. Fiberoptic bronchoscopy with bronchoal-
veolar lavage (BAL) was performed before initiating
empirical antibiotic therapy with piperacillin-tazobactam
and ofloxacin. Microbiological examination of the BAL
fluid evidenced the presence of mycelia, hence the addi-
tion of fluconazole to the treatment. On day 23, the
patient deteriorated and was admitted to the ICU (Simpli-
fied Acute Physiology Score II -SAPS2-61, Organ dysfunc-
tion and/or Infection -ODIN 4/7). The chest x-ray
radiograph showed bilateral diffuse alveolar opacities.
The patient was mechanically ventilated (PaO2/FiO2158
mmHg). The total neutrophil count was 21,000/mm3
(lymphocytes 219/mm3). Blood and urine samples, pleu-
ral and peritoneal fluids, and all catheters yielded negative
cultures. Microbiological examination of repeated BAL
fluid (performed on day 24) was negative, but the
aspergillosis latex antigen agglutination test was positive
at 1/256 (Platelia Aspergillus EIA for immunoenzymatic
detection of galactomannan antigen of Aspergillus in
serum; Bio-Rad, Marnes la Coquette, France). Aspergillus
serology was negative (Protide Immunoelectrophoresis
Aspergillus FSK1-MICROGEN, Beckman-Coulter, Fuller-
ton, USA). Blood aspergillosis antigen tests (Platelia
Aspergillus EIA for immunoenzymatic detection of galac-
tomannan antigen of Aspergillus in serum; Bio-Rad,
Marnes la Coquette, France) were positive on two occa-
sions (possible false positive in the first instance because
of the administration of piperacillin-tazobactam [6,7]).
Fluconazole was switched to intravenous voriconazole
(loading dose 400 mg two times on day 1, maintenance
dose 200 mg twice daily) on day 27. The patient died on
day 29. The family refused necropsy.
Case 2
A 55-year-old man was first admitted for severe pneumo-
nia with rhabdomyolysis, acute renal failure and enceph-
alopathy, revealing Child-Pugh stage C12 alcoholic
cirrhosis. Empirical antibiotic therapy with piperacillin-
tazobactam and ofloxacin was started. The serology tests
for HIV, HBV and HCV were negative. On day 2, septic
shock developed and the patient was transferred to the
ICU (SAPS2 92; ODIN 5/7). He was mechanically venti-
lated (PaO2/FiO2 104 mmHg), placed under continuous
hemodiafiltration, and received hemodynamic support
plus intravenous hydrocortisone hemisuccinate (50 mg
every 6 hours, 6 days). Upon the results of initial blood
cultures idenfying Streptococcus pneumoniae as the likely
cause of the pneumonia, antibiotic therapy was switched
to high dose amoxycillin (6 g daily). The patient
improved. He could be weaned from mechanical ventila-
tion after two weeks, and from continuous hemodiafiltra-
tion after three weeks. Mechanical ventilation was
resumed two weeks later because of a catheter-related Sta-
phylococcus infection causing septic shock. After one addi-
tional week, new bilateral pulmonary infiltrates appeared.
Microbiological examination of BAL fluid was negative for
bacteria, while the histopathological examination yielded
signs of alveolar damage with alveolar hemosiderosis
(Golde score 38). At this time, the total leucocyte count
was 8,600/mm3 (258 lymphocytes). BAL fluid and
plugged telescopic catheter specimen grew Aspergillus
fumigatus (five colonies). Two serum aspergillosis antigen
tests were positive at a four days interval, both at 6.3 ng/
ml (Platelia Aspergillus EIA for immunoenzymatic detec-
tion of galactomannan antigen of Aspergillus in serum;
Bio-Rad, Marnes la Coquette, France). Aspergillus serology
was negative (Protide Immunoelectrophoresis Aspergillus
FSK1-MICROGEN, Beckman-Coulter, Fullerton, USA).
Intravenous voriconazole was prescribed (loading dose
400 mg two times on day 1, maintenance dose 200 mg
twice daily) but the patient developed multiple organ fail-
ure and died on the second day of this treatment. The fam-
ily refused necropsy.
Case 3
A 64-year-old woman with a C14 alcoholic cirrhosis
(Child Pugh score) and a histologically proven alcoholic
hepatitis was admitted after one month of oral corticoster-
oid therapy, with a diagnosis of hepatic encephalopathy,
in the context of a Klebsiella urinary tract infection. Amox-
icillin/clavulanic acid was prescribed. The serology tests
for HIV, HBV and HCV were negative. Over the week fol-
lowing admission, the patient developed acute respiratory
failure, with bilateral pulmonary infiltrates and severe
hypoxemia (PaO2 57 mmHg with oxygen 10 L/min).
There was fever (38.5°C) and a total leucocyte count of
10,100/mm3 (300 lymphocytes). The patient was trans-
ferred to the ICU (SAPS2 39, ODIN 3/7) and fiberopticPage 2 of 4
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tion of BAL fluid and bronchial aspiration showed
hyphae, and both types of sample grew Aspergillus fumiga-
tus. No other infectious agents were identified. Aspergillo-
sis antigen tests were negative (Platelia Aspergillus EIA for
immunoenzymatic detection of galactomannan antigen
of Aspergillus in serum; Bio-Rad, Marnes la Coquette,
France). The Aspergillus agglutination test was positive
with one arch and a titer of 1/320 (Protide Immunoelec-
trophoresis Aspergillus FSK1-MICROGEN, Beckman-
Coulter, Fullerton, USA). Intravenous voriconazole was
prescribed (loading dose 400 mg two times on day 1,
maintenance dose 200 mg twice daily). The patient devel-
oped multiple organ failure with severe hepatic dysfunc-
tion and died 2 weeks after admission (third day of
voriconazole treatment). The family refused necropsy.
Conclusion
Although they did not meet the host-related criteria of the
European Organisation for Research and Treatment of
Cancer (EORTC), the first two of our cases fulfilled the
definition of "probable" invasive pulmonary aspergillosis
[1]. The third case fulfilled one host-related criteria (pro-
longed administration of systemic corticosteroids in the
previous 60 days) and also qualified as "probable" on the
EORTC grid [1]. Because there was no Aspergillus culture
from a normally sterile site, no tissue biopsy and no
necropsy, none of the cases can be classified as "proven".
We however believe that these three patients who rapidly
developed bilateral pulmonary infiltrates indeed suffered
from invasive aspergillosis. Indeed, in the three cases, ele-
ments suggestive of the presence of Aspergillus were
present concomittantly in respiratory samples and in the
blood, whereas the non-mycologic microbiological
workup was consistently negative. Of note, CT scans could
not be performed, so we do not know whether the halo
sign, considered of high diagnostic value in cancer
patients, was present or not. The value of this sign is yet to
be ascertained in critically ill patients. Similarly, our
patients did not exhibit wheezes or hemoptysis, which are
important clinical signs of invasive pulmonary aspergillo-
sis.
Our patients presented several possible risk factors for
invasive pulmonary aspergillosis. Steroid exposure was
noted in the three cases, even though the EORTC host-
related criteria were met in only one case. In one case, ster-
oid exposure only consisted in the short duration stress
dose of hydrocortisone that is currently routinely used in
septic shock, but is has been shown shown that hydrocor-
tisone promotes the growth of aspergillus in vitro [8]. In
addition, it could be speculated that in critically ill
patients, the threshold dose of corticosteroid that
increases the risk of invasive aspergillosis is lower than in
other patients because of the possible state of immunopa-
ralysis associated with critical illness [9]. Corticosteroids
are also known to promote aspergillosis in patients with
underlying lung lesions [10]. These elements strengthen
the notion that corticosteroids should be used with cau-
tion in critically ill patients. They suggest that in the pres-
ence of Aspergillus infection, stopping or tapering such
treatments should at least be the matter of discussion. Of
note, previous lung disease and lung structural damage
due to pneumonia or acute respiratory distress syndrome
were present in the three cases, and could have intrinsi-
cally promoted invasive aspergillosis [11]. Importantly,
the three patients exhibited severe hepatic dysfunction.
This condition deteriorates the host defense capacity. Cir-
rhosis is strongly associated with an increased risk of sep-
sis and acute respiratory failure [12]. Opportunistic
infections usually associated with profound immunosup-
pression have been reported in cirrhotic patients other-
wise free of immunosuppressive conditions or treatments
[13]. T-lymphocyte count is inversely related to the sever-
ity of cirrhosis [14]. In addition, as mentioned in the
introduction, acute liver failure promotes fungal infec-
tions [5]. Therefore, the occurrence of invasive pulmonary
aspergillosis in patients with severe liver failure is not
really surprising. It has been described in solid organ
transplant recipients [15] including liver transplant recip-
ients [16]. In the three patients described here, the overall
leukocyte counts were normal but the the lymphocyte
counts were very low at the time of diagnosis, and always
dramatically lower than upon admission. We therefore
consider these three patients as severely immunocompro-
mised. This may contribute to explain why Aspergillus
serology was negative in the first two patients and only
weakly positive in the third one, a common finding in the
presence of immunosuppression [17].
Finally, it must be noted that the fatal outcome in the
three cases that we describe is not suprising in view of the
very high mortality expected from the SAPS values at the
outset and of the dismal prognosis of severe sepsis and
multiple organ failure in patients with advanced liver fail-
ure.
This case series fuels the hypothesis that severe, decom-
pensated liver cirrhosis may be considered as a host risk
factor for the development of invasive aspergillosis [3].
However, this assumption should be put into perspective,
since in all cases other risk factors for opportunistic infec-
tion were present, such as steroid exposure, antibiotic use
and severe critical illness. In patients with advanced or
decompensated liver cirrhosis and pneumonia, a primary
or secondary fungal origin should be considered, if infil-
trates progress in spite of adequate antibiotic therapy and
respiratory insufficiency develops. Further diagnostic
exploration is mandatory, including bronchoscopy and
lavage, mycological sampling, and serology for Aspergil-Page 3 of 4
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lus antigen. Medical imaging may be contributive, but is
less pathognomonic than in neutropenic patients. Early
pre-emptive treatment with antifungals is warranted.
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